Epigallocatechin gallate inhibits growth and epithelial-to-mesenchymal transition in human thyroid carcinoma cell lines

Journal of Cellular Physiology

Volumn 228, Issue 10, 2013, Pages 2054-2062

  De Amicis, Francesca ^a   Perri, Anna ^a,b   Vizza, Donatella ^b   Russo, Alessandra ^a   Panno, Maria Luisa ^a   Bonofiglio, Daniela ^a   Giordano, Cinzia ^a   Mauro, Loredana ^a   Aquila, Saveria ^a   Tramontano, Donatella ^c   Andò, Sebastiano ^a  

^a UNIVERSITY OF CALABRIA   (Italy)

^b Annunziata Hospital   (Italy)

^c UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA5 INTEGRIN; CYCLIN D1; CYCLIN DEPENDENT KINASE INHIBITOR 1; EPIGALLOCATECHIN GALLATE; GELATINASE B; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; NERVE CELL ADHESION MOLECULE; PROTEIN KINASE B; PROTEIN P21; PROTEIN P53; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR SNAIL; TRANSCRIPTION FACTOR TWIST; TRANSCRIPTION FACTOR ZEB; UNCLASSIFIED DRUG; UVOMORULIN; VIMENTIN;

ACTIN FILAMENT; ARTICLE; CANCER INHIBITION; CARCINOMA CELL; CELL MIGRATION; CELL MOTILITY; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; EPITHELIAL MESENCHYMAL TRANSITION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; THYROID FOLLICULAR CARCINOMA; THYROID PAPILLARY CARCINOMA; UPREGULATION; WESTERN BLOTTING; ZYMOGRAPHY;

ACTINS; APOPTOSIS; CADHERINS; CATECHIN; CELL ADHESION; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; CYCLIN D1; CYCLIN-DEPENDENT KINASE INHIBITOR P21; DOWN-REGULATION; EPITHELIAL-MESENCHYMAL TRANSITION; HOMEODOMAIN PROTEINS; HUMANS; INTEGRIN ALPHA5; MAP KINASE SIGNALING SYSTEM; MATRIX METALLOPROTEINASE 9; NUCLEAR PROTEINS; PROTO-ONCOGENE PROTEINS C-AKT; THYROID NEOPLASMS; TRANSCRIPTION FACTORS; TUMOR SUPPRESSOR PROTEIN P53; TWIST TRANSCRIPTION FACTOR; UP-REGULATION; VIMENTIN;

EID: 84879520790     PISSN: 00219541     EISSN: 10974652     Source Type: Journal    
DOI: 10.1002/jcp.24372     Document Type: Article

References (57)

1. Annabi B, Lachambre MP, Bousquet-Gagnon N, Page M, Gingras D, Beliveau R. 2002. Green tea polyphenol (-)-epigallocatechin 3-gallate inhibits MMP-2 secretion and MT1-MMP-driven migration in glioblastoma cells. Biochimica et Biophysica Acta 1542:209-220.
2. Baker AH, Edwards DR, Murphy G. 2002. Metalloproteinase inhibitors: Biological actions and therapeutic opportunities. J Cell Sci 115:3719-3727.
3. Banyard J, Zetter BR. 1999. The role of cell motility in prostate cancer. Cancer Metastasis Rev 17:449-458.
4. Basolo F, Giannini R, Toniolo A, Casalone R, Nikiforova M, Pacini F, Elisei R, Miccoli P, Berti P, Faviana P, Fiore L, Monaco C, Pierantoni GM, Fedele M, Nikiforov YE, Santoro M, Fusco A. 2002. Establishment of a non-tumorigenic papillary thyroid cell line (FB-2) carrying the RET/PTC1 rearrangement. Int J Cancer 97:608-614.
5. Batlle E, Sancho E, Francí C, Domínguez D, Monfar M, Baulida J, García De Herreros A. 2000. The transcription factor snail is a repressor of E-cadherin gene expression in epithelial tumour cells. Nat Cell Biol 2:84-89.
6. Buehler D, Hardin H, Shan W, Montemayor-Garcia C, Rush PS, Asioli S, Chen H, Lloyd RV. Expression of epithelial-mesenchymal transition regulators SNAI2 and TWIST1 in thyroid carcinomas. Mod Pathol 2013. 26:54-61.
7. Cavallaro U. 2004. N-cadherin as an invasion promoter: A novel target for antitumor therapy? Curr Opin Invest Drugs 5:1274-1278.
8. Chen C, Chang YC, Liu CL, Chang KJ, Guo IC. 2006. Leptin-induced growth of human ZR-75-1 breast cancer cells is associated with up-regulation of cyclin D1 and c-Myc and down-regulation of tumor suppressor p53 and p21(WAF1/CIP1). Breast Cancer Res Treat 98:121-132.
9. Chung FL, Schwartz J, Herzog CR, Yang YM. 2003. Tea and cancer prevention: Studies in animals and humans. J Nutrition 133:3268-3274.
10. De Amicis F, Lanzino M, Kisslinger A, Calì G, Chieffi P, Andò S, Mancini FP, Tramontano D. 2006. Loss of proline-rich tyrosine kinase 2 function induces spreading and motility of epithelial prostate cells. J Cell Phys 209:74-80.
11. De Amicis F, Zupo S, Panno ML, Malivindi R, Giordano F, Barone I, Mauro L, Fuqua SA, Andò S. 2009. Progesterone receptor B recruits a repressor complex to a half-PRE site of the estrogen receptor alpha gene promoter. Mol Endocrinol 23:454-465.
12. De Amicis F, Giordano F, Vivacqua A, Pellegrino M, Panno ML, Tramontano D, Fuqua SA, Andò S. 2011. Resveratrol, through NF-Y/p53/Sin3/HDAC1 complex phosphorylation, inhibits estrogen receptor alpha gene expression via p38MAPK/CK2 signaling in human breast cancer cells. FASEB J 25:3695-3707.
13. De Amicis F, Santoro M, Guido C, Avena P, Russo A, Aquila S. 2013. Epigallocatechin-gallate affects survival and metabolism of human sperm. Mol Nutr Food Res DOI: 10.1002/mnfr.201200560
14. De Marzo AM, Knudsen B, Chan-Tack K, Epstein JI. 1999. E-cadherin expression as a marker of tumor aggressiveness in routinely processed radical prostatectomy specimens. Urology 53:707-713.
15. Dell' Aica I, Dona M, Sartor L, Pezzato E, Garbisa S. 2002. (-) Epigallocatechin-3-gallate directly inhibits MT1-MMP activity, leading to accumulation of nonactivated MMP-2 at the cell surface. Lab Invest 82:1685-1693.
16. Derycke LD, Bracke ME. 2004. N-cadherin in the spotlight of cell-cell adhesion, differentiation, embryogenesis, invasion and signalling. Int J Dev Biol 48:463-476.
17. Donald CD, Cooper CR, Harris-Hooker S, Emmett N, Scanlon M, Cooke DB. 2001. Cytoskeletal organization and cell motility correlates with metastatic potential and state of differentiation in prostate cancer. Cell Mol Biol 47:1033-1038.
18. Engl T, Relja B, Blumenberg C, Müller I, Ringel EM, Beecken WD, Jonas D, Blaheta RA. 2006. Prostate tumor CXC-chemokine profile correlates with cell adhesion to endothelium and extracellular matrix. Life Sci 78:1784-1793.
19. Fu M, Wang C, Li Z, Sakamaki T, Pestell RG. 2004. Mini review: Cyclin D1: Normal and abnormal functions. Endocrinology 145:5439-5447.
20. Gartel AL, Radhakrishnan SK. 2005. Lost in transcription: p21 repression, mechanisms, and consequences. Cancer Res 65:3980-3985.
21. Gschwind A, Fischer OM, Ullrich A. 2004. The discovery of receptor tyrosine kinases: Targets for cancer therapy. Nat Rev Cancer. 4:361-370.
22. Guido C, Panza S, Santoro M, Avena P, Panno ML, Perrotta I, Giordano F, Casaburi I, Catalano S, De Amicis F, Sotgia F, Lisanti MP, Andò S, Aquila S. 2012. Estrogen receptor beta (ERβ) produces autophagy and necroptosis in human seminoma cell line through the binding of the Sp1 on the phosphatase and tensin homolog deleted from chromosome 10 (PTEN) promoter gene. Cell Cycle 11:2911-2921.
23. Gupta S, Hastak K, Afaq F, Ahmad N, Mukhtar H. 2004. Essential role of caspases in epigallocatechin-3-gallate-mediated inhibition of nuclear factor kappa B and induction of apoptosis. Oncogene 23:2507-2522.
24. Hsieh TC, Wu JM. 2008. Suppression of cell proliferation and gene expression by combinatorial synergy of EGCG, resveratrol and gamma-tocotrienol in estrogen receptor-positive MCF-7 breast cancer cells. Int J Oncol 33:851-859.
25. Isemura M, Suzuki Y, Satoh K, Narumi K, Motomiya M. 1993. Effects of catechins on the mouse lung carcinoma cell adhesion to the endothelial cells. Cell Biol Int 17:5564-5595.
26. Kanwar J, Taskeen M, Mohammad I, Huo C, Chan TH, Dou QP. 2012. Recent advances on tea polyphenols. Frontiers Biosci 4:111-131.
27. Katiyar SK, Mukhtar H. 1996. Tea in chemoprevention of cancer: Epidemiologic and experimental studies. Int J Oncol 8:221-238.
28. Khan N, Adhami VM, Mukhtar H. 2009. Review: Green tea polyphenols in chemoprevention of prostate cancer: Preclinical and clinical studies. Nutr Cancer 61:836-841.
29. Laptenko O, Prives C. 2006. Transcriptional regulation by p53: One protein, many possibilities. Cell Death Differ 13:951-961.
30. Lim YC, Cha YY. 2011. Epigallocatechin-3-gallate induces growth inhibition and apoptosis of human anaplastic thyroid carcinoma cells through suppression of egfr/erk pathway and cyclin B1/CDK1 complex. J Surg Oncol 104:776-780.
31. Mazzaferri EL. 1999. An overview of the management of papillary and follicular thyroid carcinoma. Thyroid 9:421-427.
32. Mima K, Hayashi H, Kuroki H, Nakagawa S, Okabe H, Chikamoto A, Watanabe M, Beppu T, Baba H. 2013. Epithelial-mesenchymal transition expression profiles as a prognostic factor for disease-free survival in hepatocellular carcinoma: Clinical significance of transforming growth factor-β signaling. Oncol Lett 5:149-154.
33. Mittal A, Pate MS, Wylie RC, Tollefsbol TO, Katiyar SK. 2004. EGCG down-regulates telomerase in human breast carcinoma MCF-7 cells, leading to suppression of cell viability and induction of apoptosis. Int J Oncol 24:703-710.
34. Moiseeva EP, Almeida GM, Jones GD, Manson MM. 2007. Extended treatment with physiologic concentrations of dietary phytochemicals results in altered gene expression, reduced growth, and apoptosis of cancer cells. Mol Cancer Therap 6:3071-3079.
35. Noel A, Albert V, Bajou K, Bisson C, Devy L, Frankenne F, Maquoi E, Masson V, Sounni NE, Foidart JM. 2001. New functions of stromal proteases and their inhibitors in tumor progression. Surg Oncol Clin N Am 10:417-432.
36. Paschka AG, Butler R, Young CY. 1998. Induction of apoptosis in prostate cancer cell lines by the green tea component, (-)-epigallocatechin-3-gallate. Cancer Lett 130:1-7.
37. Peinado H, Portillo F, Cano A. 2004. Transcriptional regulation of cadherins during development and carcinogenesis. Int J Dev Biol 48:365-375.
38. Pongracz JE, Stockley RA. 2006. Wnt signalling in lung development and diseases. Respir Res 7:15.
39. Rouet-Benzineb P, Aparicio T, Guilmeau S, Pouzet C, Descatoire V, Buyse M, Bado A. 2004. Leptin counteracts sodium butyrate-induced apoptosis in human colon cancer HT-29 cells via NF-kappaB signaling. J Biol Chem 279:16495-16502.
40. Saeki K, Kobayashi N, Inazawa Y, Zhang H, Nishitoh H, Ichijo H, Saeki K, Isemura M, Yuo A. 2002. Oxidation-triggered c-Jun N-terminal kinase (JNK) and p38 mitogen-activated protein (MAP) kinase pathways for apoptosis in human leukaemic cells stimulated by epigallocatechin-3-gallate (EGCG): a distinct pathway from those of chemically induced and receptor-mediated apoptosis. Biochem J 368:705-720.
41. Santoro M, Carlomagno F, Melillo RM, Fusco A. 2004. Dysfunction of the RET receptor in human cancer. Cell Mol Life Sci 61:2954-2964.
42. Sarkar FH, Li Y, Wang Z, Kong D. 2009. Cellular signaling perturbation by natural products. Cell Signal 21:1541-1547.
43. Saxena NK, Sharma D, Ding X, Lin S, Marra F, Merlin D, Anania FA. 2007. Concomitant activation of the JAK/STAT, PI3K/AKT, and ERK signaling is involved in leptin-mediated promotion of invasion and migration of hepatocellular carcinoma cells. Cancer Res 67:2497-2507.
44. Sawada K, Mitra AK, Radjabi AR, Bhaskar V, Kistner EO, Tretiakova M, Jagadeeswaran S, Montag A, Becker A, Kenny HA, Peter ME, Ramakrishnan V, Yamada SD, Lengyel E. 2008. Loss of E-cadherin promotes ovarian cancer metastasis via alpha 5-integrin, which is a therapeutic target. Cancer Res 68:2329-2339.
45. Shi ST, Wang ZY, Smith TJ, Hong JY, Chen WF, Ho CT, Yang CS. 1994. Effects of green tea and black tea on 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone bioactivation, DNA methylation, and lung tumorigenesis in A/J mice. Cancer Res 54:4641-4647.
46. Surh, Y.J. 2003. Cancer chemoprevention with dietary phytochemicals. Nat Rev Cancer 3:768-780.
47. Tantivejkul K, Kalikin LM, Pienta KJ. 2004. Dynamic process of prostate cancer metastasis to bone. J Cell Biochem 91:706-717.
48. Thiery JP, Acloque H, Huang RY., et al. 2009. Epithelial-mesenchymal transitions in development and disease. Cell 139:871-890.
49. Villone G, De Amicis F, Veneziani BM, Salzano S, Di Carlo A, Tramontano D. 1997. Sustained versus transient cyclic AMP intracellular levels: Effect on thyrotropin-dependent growth of thyroid cells. Cell Growth Differ 8:1181-1188.
50. Vivacqua A, Lappano R, De Marco P, Sisci D, Aquila S, De Amicis F, Fuqua SA, Andò S, Maggiolini M. 2009. G protein-coupled receptor 30 expression is up-regulated by EGF and TGF alpha in estrogen receptor alpha-positive cancer cells. Mol Endocrinol 23:1815-1826.
51. Von Pressentin MM, Chen M, Guttenplan JB. 2001. Mutagenesis induced by 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone-4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone and N-nitrosonornicotine in lacZ upper aerodigestive tissue and liver and inhibition by green tea. Carcinogenesis 22:203-206.
52. Wexler JA. 2011. Approach to the thyroid cancer patient with bone metastases. J Clin Endocrinol Metabol 96:2296-2307.
53. Xing M. 2010. Genetic alterations in the phosphatidylinositol-3 kinase/Akt pathway in thyroid cancer. Thyroid 20:697-706.
54. Yamamura T, Nakanishi K, Hiroi S, Kumaki F, Sato H, Aida S, Kawai T. 2002. Expression of membrane-type-1-matrix metalloproteinase and metalloproteinase-2 in nonsmall cell lung carcinomas. Lung Cancer 35:249-255.
55. Yang H, Landis-Piwowar K, Chan TH, Dou QP. 2011. Green tea polyphenols as proteasome inhibitors: Implication in chemoprevention. Curr Cancer Drug Targets 11:296-306.
56. Yang J, Wei D, Liu J. 2005. Repressions of MMP-9 expression and NFkappa B localization are involved in inhibition of lung carcinoma 95-D cell invasion by (-)-epigallocatechin-3-gallate. Biomed Pharmacother 59:98-103.
57. Yuan JM, Sun C, Butler LM. 2011. Tea and cancer prevention: epidemiological studies. Pharmacol Res 64:123-135.